

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Paravision 6.0.1

Data analysis

Matlab R2018b, Prism 8, AFNI 18.2.15

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

Raw datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

|                 |   |
|-----------------|---|
| Sample size     | Replicates were performed to ensure reproducibility of measurements, not to meet explicit statistical criteria. Sample sizes for in vivo experiments were sufficient to report the observed effect sizes with appropriate statistical confidence. |
| Data exclusions | No data was excluded.   |
| Replication     | All experiments were replicated to ensure reproducibility and enable measurement of mean effect sizes.  |
| Randomization   | Not performed.  |
| Blinding        | Not performed.  |

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

| n/a                                 | Included in the study   |
|-------------------------------------|---|
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Antibodies                  |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Eukaryotic cell lines       |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Palaeontology                          |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> Animals and other organisms |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Human research participants            |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Clinical data                          |

### Methods

| n/a                                 | Included in the study                                      |
|-------------------------------------|--|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> ChIP-seq                          |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Flow cytometry                    |
| <input type="checkbox"/>            | <input checked="" type="checkbox"/> MRI-based neuroimaging |

## Antibodies

|                 |  |
|-----------------|--|
| Antibodies used | Anti-Dopamine antibody ab6427 (Abcam, Cambridge, MA)   |
| Validation      | <p>Antibody is commercially available and validation was performed by manufacturer and was supported by multiple publications: Fink J et al. Development of a Competition-Binding Assay to Determine Binding Affinity of Molecules to Neuromelanin via Fluorescence Spectroscopy. <i>Biomolecules</i> 9:175 (2019).</p> <p>Taylor-Whiteley TR et al. Recapitulating Parkinson's disease pathology in a three-dimensional human neural cell culture model. <i>Dis Model Mech</i> 12:dmm038042 (2019).</p> <p>Banks DA et al. MK-STYX Alters the Morphology of Primary Neurons, and Outgrowths in MK-STYX Overexpressing PC-12 Cells Develop a Neuronal Phenotype. <i>Front Mol Biosci</i> 4:76 (2017).</p> <p>Wu SF et al. Dopamine modulates hemocyte phagocytosis via a D1-like receptor in the rice stem borer, <i>Chilo suppressalis</i>. <i>Sci Rep</i> 5:12247 (2015).</p> <p>Forati E et al. Neurotransmitter Specific, Cellular-Resolution Functional Brain Mapping Using Receptor Coated Nanoparticles: Assessment of the Possibility. <i>PLoS One</i> 10:e0145852 (2015).</p> |

## Eukaryotic cell lines

Policy information about [cell lines](#)

|   |  |
|---|--|
| Cell line source(s)   | CHO K1 (Sigma-Aldrich, St. Louis, MO), HEK293FT (Life Technologies, Grand Island, NY)                          |
| Authentication  | All cell lines are commercially available and validation was performed by manufacturer.                        |
| Mycoplasma contamination  | Cell lines tested negative for mycoplasma contamination in the MycoAlert assay (Lonza, Walkersville, MD, USA). |
| Commonly misidentified lines (See <a href="#">ICLAC</a> register) | No commonly misidentified cell lines were used.  |

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

|                         |  |
|-------------------------|--|
| Laboratory animals      | All experiments were performed with male Sprague-Dawley rats, age 7–9 weeks, supplied by Charles River Laboratories (Wilmington, MA). Seventeen rats were used for in vivo imaging experiments described here. |
| Wild animals            | No wild animals were used in the study.  |
| Field-collected samples | No field samples were collected in the study.  |
| Ethics oversight        | All animal procedures were conducted in accordance with National Institutes of Health guide-lines and with the approval of the MIT Committee on Animal Care (protocol number 0718-068-21).                     |

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Magnetic resonance imaging

### Experimental design

|                                 |   |
|---------------------------------|---|
| Design type                     | Event-related response (event = infusion of vasoprobe/AVATar)   |
| Design specifications           | Figure 1 experiment: 10 minutes baseline, followed by 10 minutes of vasoprobe infusion, followed by 20 minutes of follow-up scanning<br>Figure 4 experiment: 10 minutes baseline, followed by continuous infusion of AVATar |
| Behavioral performance measures | No behavioral performance measured.   |

### Acquisition

|                               |   |
|-------------------------------|---|
| Imaging type(s)               | anatomical, functional, and T1-weighted   |
| Field strength                | 7 Tesla   |
| Sequence & imaging parameters | High resolution T2-weighted anatomical scans of each animal were obtained using a rapid acquisition with relaxation enhancement (RARE) pulse sequence with echo time (TE) 44 ms, re-cycle time (TR) 2,500 ms, RARE factor 8, spatial resolution 100 $\mu\text{m}$ x 100 $\mu\text{m}$ x 1 mm, and matrix size 256 x 256 with seven slices. Hemodynamic contrast image series were acquired using a gradient echo planar imaging (EPI) pulse sequence with TE 25 ms, TR 2,000 ms, spatial resolution 390 $\mu\text{m}$ x 390 $\mu\text{m}$ x 1 mm, and matrix size 64 x 64 with seven slices. T1-weighted scans were performed using a fast lowangle shot (FLASH) pulse sequence with TE 5 ms, TR 93.75 ms, spatial resolution 400 $\mu\text{m}$ x 400 $\mu\text{m}$ x 1 mm, and matrix size 64 x 64 with seven sagittal slices. |
| Area of acquisition           | whole brain   |
| Diffusion MRI                 | <input type="checkbox"/> Used <input checked="" type="checkbox"/> Not used  |

### Preprocessing

|                            |   |
|----------------------------|---|
| Preprocessing software     | Paravision, AFNI  |
| Normalization              | Spatial registration was performed. Effects were normalized to baseline and in some cases areas of the brain not affected by sensor infusion.   |
| Normalization template     | Reference animal  |
| Noise and artifact removal | The time series data from the EPI scans were smoothed with a Gaussian spatial kernel of 1mm full-width at half-maximum prior to statistical analysis, and each voxel time course was subsequently temporally smoothed using a sliding box window of width 75. |
| Volume censoring           | Not relevant to the study.  |

### Statistical modeling & inference

|                           |  |
|---------------------------|--|
| Model type and settings   | General linear model with fixed effects.   |
| Effect(s) tested          | Event-related responses, with motion correlates regressed out  |
| Specify type of analysis: | <input checked="" type="checkbox"/> Whole brain <input type="checkbox"/> ROI-based <input type="checkbox"/> Both |

Statistic type for inference  
(See [Eklund et al. 2016](#))

F-test

Correction

None

## Models & analysis

- | n/a                                 | Involvement in the study  |
|-------------------------------------|---|
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Functional and/or effective connectivity     |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Graph analysis                               |
| <input checked="" type="checkbox"/> | <input type="checkbox"/> Multivariate modeling or predictive analysis |